&lt;p&gt;Long Noncoding RNA H19 Induces Neuropathic Pain by Upregulating Cyclin-Dependent Kinase 5-Mediated Phosphorylation of cAMP Response Element Binding Protein&lt;/p&gt;

Li, Kai; Yuan, Jiao; Ren, Xing; You, Di; Cao, Ruihua

doi:10.2147/jpr.s240273

Cited by 5 publications

(2 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The following studies were performed to explore the roles and mechanisms of lncRNAs in the development of PNI-induced CNP. lncRNAs, such as MALAT1, DILC, FIRRE, XIST, H19, and DGCR5 in the spinal cord, have been found to have a continuous effect on CNP ( Wei et al, 2018 ; Peng et al, 2019 ; Li K. et al, 2020 ; Liu et al, 2020 ; Wu et al, 2020 ; Wen et al, 2021 ). lncRNAs, such as H19, SNHG5, and MRAK009713 in DRG, have also been identified to play important roles in the development of CNP ( Li et al, 2017 ; Chen et al, 2020 ; Wen et al, 2020 ).…”

Section: Lncrnas and Chronic Neuropathic Painmentioning

confidence: 99%

Roles of Long Non-coding RNAs in the Development of Chronic Pain

Jian

et al. 2021

Front. Mol. Neurosci.

View full text Add to dashboard Cite

Chronic pain, a severe public health issue, affects the quality of life of patients and results in a major socioeconomic burden. Only limited drug treatments for chronic pain are available, and they have insufficient efficacy. Recent studies have found that the expression of long non-coding RNAs (lncRNAs) is dysregulated in various chronic pain models, including chronic neuropathic pain, chronic inflammatory pain, and chronic cancer-related pain. Studies have also explored the effect of these dysregulated lncRNAs on the activation of microRNAs, inflammatory cytokines, and so on. These mechanisms have been widely demonstrated to play a critical role in the development of chronic pain. The findings of these studies indicate the significant roles of dysregulated lncRNAs in chronic pain in the dorsal root ganglion and spinal cord, following peripheral or central nerve lesions. This review summarizes the mechanism underlying the abnormal expression of lncRNAs in the development of chronic pain induced by peripheral nerve injury, diabetic neuropathy, inflammatory response, trigeminal neuralgia, spinal cord injury, cancer metastasis, and other conditions. Understanding the effect of lncRNAs may provide a novel insight that targeting lncRNAs could be a potential candidate for therapeutic intervention in chronic pain.

show abstract

Section: Lncrnas and Chronic Neuropathic Painmentioning

confidence: 99%

Roles of Long Non-coding RNAs in the Development of Chronic Pain

Jian

et al. 2021

Front. Mol. Neurosci.

View full text Add to dashboard Cite

show abstract

“…Cdk5 mediated cyclic AMP response element binding protein (CREB; Li et al, 2014 ) and regulated NP through Cdk5/PPAR γ pathway (Zhong et al, 2019 ). Silencing noncoding RNA H19 can relieve by inhibiting Cdk5 mediated phosphorylation of CREB (Li et al, 2020 ). Based on these findings, Cdk5 is supposed to be a potential target to attenuate neuralgia.…”

Section: Neuropathic Pain (Np)mentioning

confidence: 99%

The role of Cdk5 in neurological disorders

Chen

et al. 2022

Front. Cell. Neurosci.

View full text Add to dashboard Cite

Neurological disorders are a group of disorders with motor, sensory or cognitive damage, caused by dysfunction of the central or peripheral nervous system. Cyclin-dependent kinases 5 (Cdk5) is of vital significance for the development of the nervous system, including the migration and differentiation of neurons, the formation of synapses, and axon regeneration. However, when the nervous system is subject to pathological stimulation, aberrant activation of Cdk5 will induce abnormal phosphorylation of a variety of substrates, resulting in a cascade signaling pathway, and thus lead to pathological changes. Cdk5 is intimately related to the pathological mechanism of a variety of neurological disorders, such as A-β protein formation in Alzheimer’s disease, mitochondrial fragmentation in cerebral ischemia, and apoptosis of dopaminergic neurons in Parkinson’s disease. It is worth noting that Cdk5 inhibitors have been reported to have neuroprotective effects by inhibiting related pathological processes. Therefore, in this review, we will briefly introduce the physiological and pathological mechanisms of Cdk5 in the nervous system, focusing on the recent advances of Cdk5 in neurological disorders and the prospect of targeted Cdk5 for the treatment of neurological disorders.

show abstract